2012: A Good, Bad or Ugly Year for Servier? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

2012: A Good, Bad or Ugly Year for Servier?
The scandal surrounding Servier's diabetes drug, Mediator, continues to unravel in France and could have implications for the whole pharmaceutical industry as the country scrutinises its regulatory systems.


Pharmaceutical Technology Europe
Volume 24, Issue 2

References

1. E. Lanez, "Mediator : l'effarante boîte à mensonges" (Le Point.fr, 2011) http://www.lepoint.fr, accessed Jan. 9, 2012.

2. B. Casassus, "With New Law, France Revamps Drug Approval" (Science, 2011). http://news.sciencemag.org/, accessed Jan. 9, 2012.

3. Servier, "Research is as vital as being an industry " (Servier website, 2011). http://www.servier.com/, accessed 9 Jan., 2012.

4. J. Upton, "Servier: patience and passion," Pharmaceutical Executive Europe (November 2008).

5. Focus Reports, "Interview—Jacques Servier" (2011). http://www.pharma.focusreports.net/, accessed 9 Jan., 2012.

6. K. Grogan, "Servier signs cancer deal with Sweden's BioInvent" (Pharma Times, 2012). http://www.pharmatimes.com/, accessed Jan. 9, 2012.

7. European Biotechnology Science & Industry News "Galapagos gets €4 million in alliance with Servier" (2011). http://www.eurobiotechnews.eu, accessed 9 Jan., 2012.

8. N. Jessop, Pharm. Technol. Eur. 23 (3), 14–18 (2011).

9. Le Point.fr, "Mediator, un jugement pour 2012?" (2011). http://www.lepoint.fr, accessed Jan. 9, 2012.

10. S. Sayare, "Scandal Over Mediator, a French Weight-Loss Drug, Prompts Calls for Wide Changes" (New York Times, 2011). http://www.nytimes.com/, accessed Jan. 9, 2012

11. Assemblée Nationale (2011). http://www.assemblee-nationale.fr/13/rap-info/i3552.asp, accessed Jan. 11, 2012

12. InPharm, "2011 Year In Review" (2012). http://www.inpharm.com/, accessed Jan. 9, 2012.

13. Le Nouvel Observateur, "Mediator: la cour rejette le regroupement des procédures" (2011). http://tempsreel.nouvelobs.com/, accessed Jan. 11, 2012.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here